TP53 Deletion is Not an Adverse Feature in Multiple Myeloma Treated with Total Therapy 3

Contrary to Total Therapy 2 (TT2), FGFR3-translocation bore no adverse effects on outcome in Total Therapy 3 (TT3) with added bortezomib. DelTP53, another poor-risk feature in TT2, was examined for its prognostic consequences in TT3 present in 10% of 441 patients treated. Not affecting rate or durat...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Shaughnessy, John D, Zhou, Yiming, Haessler, Jeff, van Rhee, Frits, Anaissie, Elias, Nair, Bijay, Waheed, Sarah, Alsayed, Yazan, Epstein, Joshua, Crowley, John, Barlogie, Bart
Formato: Artigo
Idioma:Inglês
Publicado: 2009
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3675654/
https://ncbi.nlm.nih.gov/pubmed/19702643
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2141.2009.07864.x
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares